These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35249370)

  • 21. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
    Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
    Kazi DS; Penko J; Coxson PG; Guzman D; Wei PC; Bibbins-Domingo K
    Ann Intern Med; 2019 Feb; 170(4):221-229. PubMed ID: 30597485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes.
    Li T; Wan X; Ma J; Wu B
    Adv Ther; 2018 Dec; 35(12):2214-2223. PubMed ID: 30390239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease.
    Špacírová Z; Kaptoge S; García-Mochón L; Rodríguez Barranco M; Sánchez Pérez MJ; Bondonno NP; Tjønneland A; Weiderpass E; Grioni S; Espín J; Sacerdote C; Schiborn C; Masala G; Colorado-Yohar SM; Kim L; Moons KGM; Engström G; Schulze MB; Bresson L; Moreno-Iribas C; Epstein D
    Eur J Health Econ; 2023 Sep; 24(7):1033-1045. PubMed ID: 36239877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis.
    Boettiger DC; Chattranukulchai P; Avihingsanon A; Chaiwarith R; Khusuwan S; Law MG; Ross J; Kiertiburanakul S
    PLoS One; 2021; 16(9):e0256926. PubMed ID: 34499685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines.
    Pandya A; Weinstein MC; Salomon JA; Cutler D; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):25-32. PubMed ID: 24425701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
    J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
    de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
    Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
    Heller DJ; Coxson PG; Penko J; Pletcher MJ; Goldman L; Odden MC; Kazi DS; Bibbins-Domingo K
    Circulation; 2017 Sep; 136(12):1087-1098. PubMed ID: 28687710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.
    Gaziano TA; Opie LH; Weinstein MC
    Lancet; 2006 Aug; 368(9536):679-86. PubMed ID: 16920473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
    Reckless J; Davies G; Tunceli K; Hu XH; Brudi P
    Value Health; 2010; 13(6):726-34. PubMed ID: 20561328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis.
    Morton JI; Marquina C; Lloyd M; Watts GF; Zoungas S; Liew D; Ademi Z
    Pharmacoeconomics; 2024 Jan; 42(1):91-107. PubMed ID: 37606881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment.
    Weintraub WS; Bhatt DL; Zhang Z; Dolman S; Boden WE; Bress AP; King JB; Bellows BK; Tajeu GS; Derington CG; Johnson J; Andrade K; Steg PG; Miller M; Brinton EA; Jacobson TA; Tardif JC; Ballantyne CM; Kolm P
    JAMA Netw Open; 2022 Feb; 5(2):e2148172. PubMed ID: 35157055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Polygenic Risk Scores to Guide Statin Therapy for Cardiovascular Disease Prevention.
    Kiflen M; Le A; Mao S; Lali R; Narula S; Xie F; Paré G
    Circ Genom Precis Med; 2022 Oct; 15(5):e003423. PubMed ID: 35904973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
    Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
    Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.
    Aarnio E; Korhonen MJ; Huupponen R; Martikainen J
    Atherosclerosis; 2015 Mar; 239(1):240-7. PubMed ID: 25618032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP; Visseren FL; de Wit GA; Algra A
    BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.
    Ganz DA; Kuntz KM; Jacobson GA; Avorn J
    Ann Intern Med; 2000 May; 132(10):780-7. PubMed ID: 10819700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.